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ABSTRACT 
 
We studied the immune response after starting antiretroviral treatment (ART) in 
15,646 HIV-infected patients with or without tuberculosis (TB) at presentation in three 
ART programs in South Africa between 2003-2010. Patients presenting with TB had 
similar increases in CD4 cells compared to all other patients (adjusted difference 4.9 
cells/µl per six months, 95% CI 0.2-9.7). Younger age, advanced clinical stage, female 
sex, and lower CD4 cell count at ART start were all associated with steeper CD4 slopes. 
In South Africa HIV-infected patients presenting with TB experience immune recovery 
after starting ART that is no worse than in other patients. 
 
 
Key words: tuberculosis; HIV; antiretroviral treatment; immune response; CD4 cell 
count; linear mixed model 
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INTRODUCTION 
 
In many resource-constrained settings tuberculosis (TB) is the most common 
AIDS-defining opportunistic infection (OI),1 and is the leading cause of death in patients 
initiating antiretroviral treatment (ART) in sub-Saharan Africa.2 TB and other OIs may 
play an important role in immune recovery after ART initiation.3;4 HIV viral replication is 
enhanced by co-infection with Mycobacterium tuberculosis due to immune activation, 
which could in turn accelerate the depletion of CD4 cells by virus-induced immune 
destruction or apoptosis of lymphocytes.5-7 TB treatment is associated with decreased 
immune activation, after an initial increase during the first month of treatment 
presumably resulting from release of mycobacterial antigens.5 
A recent European study showed an impaired CD4 count recovery among HIV-
infected patients presenting with TB at ART initiation.4 There are limited data on the 
influence of different OIs on immune recovery after starting ART in sub-Saharan Africa 
and other resource-constrained settings. 
We analyzed data from three ART programs in South Africa with access to 
routine CD4 cell count and HIV viral load monitoring to study the immune response after 
starting ART in adult patients with and without concurrent TB. 
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METHODS 
 
We analyzed data from adult patients starting ART between January 1, 2003 and 
December 31, 2010 in three South African treatment programs that participate in the 
International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA, 
www.iedea-sa.org) 8 collaboration and systematically record OIs (Khayelitsha, Tygerberg 
and Themba Lethu Clinic). All sites provide integrated clinical care services for HIV and 
TB. Data are collected at each site as part of routine monitoring at enrollment and each 
follow-up visit. All study sites have local institutional review board or Ethics Committee 
approval to collect data and participate in IeDEA-SA. Inclusion criteria were age ≥16/<85 
years, and no previous ART exposure. Virologically suppressed patients (<400 HIV RNA 
copies/ml) at ART initiation and patients with less than six months of follow-up were 
excluded. The selection of eligible patients is shown in the Supplemental Digital Content 
(see Figure S1, http://links.lww.com/QAI/A389). 
A TB episode was defined as a diagnosis of TB (pulmonary/extrapulmonary) at the 
start of ART, as reported by each site. All three sites used CDC clinical and laboratory 
case definitions, however, whether the diagnosis of TB was confirmed or probable was 
not recorded in the database. To account for missing values of WHO clinical stage, CD4 
cell count and viral load at baseline and during follow-up, we generated 10 imputed 
datasets using the Amelia II package in R.9 The imputation model included age, sex, CD4 
count and slope, viral load, observation time, WHO clinical stage, TB site, and treatment 
program.10 Results were combined with Rubin’s rules.11 Patients were expected to have 
laboratory tests every six months for the purpose of determining missing follow-up 
values. 
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We used Chi-squared tests to test the statistical significance of differences 
between groups in binary variables, and the Wilcoxon rank sum test for continuous 
variables. We calculated CD4 slopes (defined as cells/µl/6 months) after starting ART up 
to four years of follow-up. We used linear mixed models to evaluate the effect of 
presenting with TB on slopes, adjusted for age, sex, CD4 count at ART start, current CD4 
cell count, time on ART, WHO clinical stage at ART initiation, and treatment program. We 
further analyzed the effect of restricting the analysis to time under continuous viral 
suppression defined as time between ART initiation and first viral load rebound (≥1,000 
copies/ml) or the last follow-up visit. We also modeled CD4 trajectories up to four years 
after starting ART by TB status, for two CD4 cell strata (<50, 50-199 cells/µl) using 
additive linear mixed models. Models included interactions of TB status with splines of 
time on ART and were adjusted for age, sex, WHO clinical stage, treatment site. Results 
for a male reference population aged 35-45 years with WHO clinical stage III from the 
Themba Lethu Clinic are shown. 
All analyses were performed in Stata version 11.2 (Stata Corporation, College 
Station, USA) and R 12.1 (R Development Core Team, Austria). 
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RESULTS 
 
We included 15,646 adult patients with a median follow-up time of 710 days 
(interquartile range [IQR] 428-1075 days), and 624 days (IQR 364-967 days) when 
restricting analyses to time under viral suppression. A total of 10,622 (67.9%) patients 
were female, and 1,052 (6.7%) had a TB diagnosis. Median age at ART initiation was 
34 years (IQR 29-40 years), median CD4 cell count 98 cells/µl (IQR 41-161 cells/µl) 
(see Supplemental Digital Content, Table S1, http://links.lww.com/QAI/A389). 
Patients presenting with TB had lower median CD4 cell counts (45 versus 102 cells/µl) 
and more advanced disease (WHO clinical stage IV 39.3% versus 26.9%) compared to 
all other patients, whereas distributions of age and sex were comparable between the 
two groups (see Supplemental Digital Content, Table S1, 
http://links.lww.com/QAI/A389). 
Patients presenting with TB at ART start gained about five CD4 cells more per six 
months than patients without TB (adjusted difference 4.9 CD4 cells/µl/6months, 95% 
confidence interval [95% CI] 0.2-9.7, p=0.04, Table 1). During the first 6 months there 
was little evidence of a difference in CD4 count change (-3.3 CD4 cells, 95% CI -15.3 to 
8.8, p=0.6). However, from six months onwards (up to 4 years of follow-up) TB patients 
were doing slightly better than patients without TB (adjusted difference 6.5 CD4 cells, 
95% CI 2.0-11.1, p=0.01). The results did not substantially change when restricting the 
analysis to time under viral suppression (Table 1). The proportion of patients with viral 
load suppression at 12 months was similar between patients presenting and not 
presenting with TB (80.9% versus 79.1%, p=0.23). 
Women had a more favorable CD4 cell response than men (adjusted difference 
2.9 cells/µl, 95% CI 0.6-5.1, p=0.01), whereas the response was less favorable in older 
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patients and patients with higher baseline CD4 cell counts (see Supplemental Digital 
Content, Table S2, http://links.lww.com/QAI/A389). 
The results from the additive linear mixed model (Figure 1) showed that patients 
presenting with TB had a similar CD4 count recovery initially, but a slightly more 
favorable trajectory in the long-term, consistent with the results for the CD4 slopes. 
Results were similar for patients with a CD4 cell count below 50 cells/µl at ART start 
and patients with a CD4 cell count between 50-199 cells/µl. Immune recovery was also 
similar in patients with pulmonary TB (adjusted difference 5.9 cells/µl, 95% CI 0.3-11.5) 
and patients with extrapulmonary TB (adjusted difference 8.6 cells/µl, 95% CI 0.7-16.5), 
compared to patients without TB at ART start. 
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DISCUSSION 
 
We analyzed HIV-infected adult patients starting ART in three large HIV 
treatment programs in South Africa. We found that overall patients presenting with TB 
did not experience a worse CD4 cell count recovery after starting ART. The results were 
similar when restricting analyses to time under viral suppression. 
Our results may be explained by several factors. First, TB infection causes 
immune activation which is associated with progression to more advanced disease.12 
Immune activation may lead to up-regulation of HIV replication, and as a result to CD4 
depletion.5 Therefore, TB treatment alone without ART has a positive effect on the 
immune system by reducing immune activation, maintaining stable HIV viral load and 
CD4 cell counts.5;13;14 Second, a survival bias may exist as the most severely ill HIV co-
infected TB patients with potentially impaired immune restoration may die before ART 
can be initiated. Therefore, a selection of patients with a better outcome may be 
reported in our dataset. Finally, patients with undiagnosed or unreported TB in the non-
TB comparison group may present with an immune reconstitution syndrome, and 
therefore may have a rapid CD4 decline.15 
Our finding extends those of a previous study from one of the included cohorts 
(the Khayelitsha ART program) which showed that receiving TB treatment at ART 
initiation was associated with an improved CD4 gain.3 In contrast to the previous 
analysis, we used mixed linear models, modeled non-linear trajectories, and imputed 
missing values. Moreover, our analyses included a larger and more representative 
dataset. Another study from South Africa also failed to show a worse immunological 
outcome among patients with TB,16 but the analysis was not restricted to time under 
viral suppression. We found no evidence for a worse immune recovery in patients with 
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extrapulmonary TB. Finally, we also demonstrated that the immune recovery was 
poorer in men and older patients, as previously shown.3;17 Interestingly, our study 
contrasts with a recent report from a high-income setting which showed that patients 
presenting with TB had impaired CD4 cell count responses to ART.4 The impaired 
immune recovery was mainly driven by a delay in achieving viral suppression.4 While 
studies from high-income settings suggested a decrease in viral load after TB treatment 
in patients with or without additional ART,18;19 we and others failed to show such an 
effect in sub-Saharan settings in patients receiving TB treatment on ART.20;21 The 
situation in European countries, however, differs from settings in sub-Saharan Africa 
with regard to the public health systems, TB screening practices, clinical follow-up, and 
patient characteristics. 
The favorable CD4 cell count immune recovery in patients with concurrent TB 
remained even when restricting analyses to time under viral suppression. Viral 
suppression is indicative of adherence to ART. HIV-infected patients on TB treatment 
may be more adherent to ART, particularly when TB treatment is directly observed. 
Similarly, the provision of cotrimoxazole or isoniazid preventive therapy has been shown 
to improve retention in care among pre-ART patients.22;23 However, we found no 
evidence, as assessed by HIV RNA suppression, for an effect of adherence. 
A limitation of our study was the potential under-ascertainment of TB as shown 
by the low prevalence of TB cases, and the lack of a uniform case definition. The under-
ascertainment of TB may have masked a worse immune recovery after starting ART in 
patients with TB compared to patients starting without known TB. However, we 
restricted our study to cohorts that systematically collect information on OIs. Our study 
may also have been influenced by OIs that occurred during follow-up, but results were 
similar when restricting analyses to time under viral suppression during which an OI 
episode is unlikely. Another limitation was the heterogeneity between the included ART 
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programs.24 To address this, we calculated relative differences adjusted for the most 
important confounding factors. 
In summary, we found that HIV-infected patients presenting with TB did not have 
a worse immune recovery after ART initiation compared to other patients. This is 
possibly due to a favorable long-term effect of the TB treatment, or factors not captured 
in our dataset, such as more frequent counseling offered to this patient group or more 
frequent clinical visits. We stress that immune recovery does not necessarily mean that 
CD4 cell function is fully restored.25 Our study underscores the benefit of co-treatment 
of HIV and TB, and indicates that management and integration of services may have a 
positive long-term effect on the immune recovery in resource-constraint settings. 
Our study needs to be confirmed in observational data from HIV cohorts with a 
high degree of diagnostic ascertainment of OIs. Further studies need to focus on 
integrated TB-HIV management and its effect on OI incidence and immune recovery 
after ART initiation. 
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Figure 1. Modeled CD4 trajectories defined as CD4 cell count increase from baseline by 
tuberculosis (TB) status at ART start, according to CD4 cell count at the start of ART of CD4 cell 
count <50 (A), and CD4 cell count between 50-199 (B).  
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Table 1. Multivariate associations with CD4 cell count changes after starting antiretroviral 
treatment (ART) comparing HIV-infected patients presenting with TB at ART start compared to all 
other patients. Results are presented as coefficient (CD4 cell count/µl/6 months), overall and 
restricted to time under viral suppression (HIV RNA viral load <1,000 copies/ml). 
 Crude  Adjusted Characteristic  
 Coefficient (95% CI) P value  Coefficient (95% CI) P value 
Unrestricted          
Overall   -5.35 (-10.67 to -0.02) 0.049  4.94 (0.20-9.68) 0.042 
First 6 months after ART start   -32.97 (-46.30 to -19.64) <0.0001  -3.25 (-15.32 to 8.81) 0.58 
>6 months after ART start   0.20 (-5.06 to 5.46) 0.94  6.51 (1.97-11.06) 0.006 
          
Restricted to time under viral 
suppression  
 
   
 
   
Overall   -7.08 (-12.56 to -1.60) 0.012  4.89 (0.06-9.73) 0.048 
First 6 months after ART start   -38.86 (-52.19 to -25.53) <0.0001  -1.29 (-13.47 to 10.87) 0.83 
>6 months after ART start   0.05 (-5.39 to 5.50) 0.99  6.22 (1.53-10.91) 0.010 
          
Models were adjusted for age, sex, CD4 cell count at ART start, current CD4 cell count, time on ART, WHO clinical 
stage, and treatment site. An interaction term between time on ART and presenting with TB at ART start was 
included in the model. 
ART, antiretroviral therapy; TB, tuberculosis; 95% CI, 95% confidence interval 
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